D’Ambrosio L, Touati N, Blay JY, et al. - Via this retrospective assessment, researchers tested doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone when administered as first‐line therapies for advanced/metastatic leiomyosarcoma managed at European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) sites. For doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone, the median progression‐free survival (PFS) was estimated to be 9.2 months, 8.2 months, and 4.8 months with overall response rates (ORRs) of 30.9%, 19.5%, and 25.6%, respectively, in the 2:1:2 propensity score–matched population (205 patients). Doxorubicin plus dacarbazine vs doxorubicin was associated with a significantly longer PFS. In this largest retrospective analysis of first‐line therapy for advanced leiomyosarcoma, favorable activity in terms of both ORR and PFS was demonstrated by doxorubicin and dacarbazine in the propensity score–matched population.